Want to see TSE:HEAL full AI Analyst Report?
HEAL Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.14
Previous CloseN/A
Volume3.00K
Average Volume (3M)3.65K
Market Cap
C$4.28M
Enterprise ValueC$2.50M
Total Cash (Recent Filing)C$1.19M
Total Debt (Recent Filing)C$354.09K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding61,077,354
10 Day Avg. Volume5,146
30 Day Avg. Volume3,650
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet StabilizationPositive equity in 2025 marks a durable improvement in solvency metrics versus prior years. For a capital‑intensive biotech, sustained positive equity reduces immediate insolvency risk, improves lender and partner confidence, and broadens strategic options for funding R&D without emergency dilutive financings.
Modest Leverage ProfileLow reported debt relative to equity provides structural financial flexibility. With minimal interest burden and modest leverage, the company has more optionality to raise capital or enter partnerships without heavy fixed obligations, which is valuable while pursuing long‑dated clinical and development milestones.
Improving Cash Outflow TrendOperating and free cash outflows remain negative but have materially improved from trough years. A sustained reduction in cash burn indicates better cost control or more efficient program execution, lengthening runway and lowering near‑term financing pressure if trends continue over the next several quarters.
Bears Say
No Recurring RevenueA multi‑year absence of revenue is a fundamental constraint: without recurring product or service sales the company must continually access external capital to fund R&D. This structural lack of operating cash inflow prevents margin development, hides commercial viability, and increases financing and execution risk.
Persistent Operating LossesConsistent negative EBIT/EBITDA shows core operations remain unprofitable, meaning any positive net income is likely non‑operational or one‑off. Long‑running operating losses erode equity, require repeated capital raises, and limit the firm's ability to fund scale-up or late‑stage trials without dilution or strategic tradeoffs.
Historical Equity VolatilityVolatile and previously negative equity signals past solvency stress and constrained financing flexibility. This history can raise borrowing costs, complicate partnership negotiations, and increase likelihood of dilutive financings if clinical or commercialization setbacks occur, posing a persistent structural risk.
Restart Life Sciences News
HEAL FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was C$0.07 and its highest was C$0.14 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is C$4.28M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Aug 21, 2026 which is in 6 days.
How were Restart Life Sciences’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 61,077,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in TSE:HEAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.